Something I wrote for another investing site last year when Dr. Hoblitzell joining BOT was announced:
A quick LinkedIn stalk and review of Dr. Hoblitzell suggests that he is a very appropriate hire at this point for the company. Dr. Hoblitzell BIOThe press release promoted him claiming he has experience leading world class technical operations to deliver new product launches (tick).Years of experience with regulatory submissions – wrangling FDA (tick).Excellence in manufacturing and supply chain management. If anyone else was around for the great acne debacle of 2019 you would get this!
CBD was a restricted drug in some states in the US and could not be transported across state lines…..nightmare. (so tick tick).Experience supporting pipeline development and ACCELERATING the development and SCALE UP for commercial capabilities (tick tick tick).
Dr. Holblitzell is a registered pharmacist.Where has he come? I note a lot of Pfizer ties revealing themselves for Botanix Pharmaceuticals. Formerly: Snr Vice President Of Technical Operations at Assertio Therapeutics Inc. May 2020-June 2021 (not there long). Assertio Therapeutics has a $0.04 Billion dollar market cap. This company specialized in pain relief drugs: diclofenac potassium, indomethacin, oxycodone Hcl.
Dr. Hoblitzell has a fairly long history of overseeing mergers of pharmaceutical companies. This is also a point that Vince Ippolito CEO has frequently addressed that Botanix is a likely buy out target with the number of product pipelines they are developing. Frequently, referencing Jazz pharmaceuticals buyout of GW pharmaceuticals for $7.2Billion for their CBD based epileptic medication.
Of course everyone invested or researching Botanix Pharmaceuticals is well aware of our illustrious CEOs background. One of the main reasons I have stayed invested. He oversaw the Pfizer buyout of Anacor Pharmaceuticals dermatology platform for $4.5Billion. Dr. Holblitzell has also been Senior Director of Pharmaceutical Technology and Global Manufacturing Services at Pfizer. Here he is endorsed by several Pfizer colleagues.
At Pfizer he was responsible for the integration of King Pharmaceutical products and processes into the Pfizer co-development and manufacturing supply networks. He was also Vice President of Technical Operations at Zyla Life Sciences for 5 years. He was endorsed by former colleagues from King Pharmaceuticals where he worked before a buyout by Pfizer. Lynn F Palmer Senior Vice President: Technical Operations of Pharmaceuticals at Osmotica Pharmaceuticals (Worked together with Dr. Holblitzell at King Pharmaceuticals) wrote:
“Jack is a practical and effective Pharmaceutical Development Executive. He has effectively led the development of multiple formulations, and scaled them up to commercial scale. He has extensive industry and technical knowledge of formulation development, product stability, pharmaceutical packaging and equipment capability and setup. I strongly endorse him. “
Pfizer’s brief: A pharmaceutical company that applies science and global resources to improve health and well-being at every stage of life. Pfizer has a $246 Billion market cap. Interesting to note Pfizer looks to “set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals.” SummaryHe seems like a great get.
A lot of tie ins with Pfizer for both he and Vince – is this the hope? A Pfizer buyout?I am really curious as to why a small Perth company with a $64 Million dollar market cap, currently trading at $0.074 per share is attracting these recruits. I certainly have my thesis – the CBD molecule patents and FDA fast track approval status achieved for their anti-microbial platforms are certainly compelling.
BOT Price at posting:
6.2¢ Sentiment: Buy Disclosure: Held
(20min delay)